复星医药芦沃美替尼片新增适应症上市申请获受理

Core Viewpoint - Fosun Pharma's subsidiary has received acceptance for the marketing application of Luwo Meitin tablets, a treatment for symptomatic, inoperable plexiform neurofibromas in adult patients with type I neurofibromatosis, which is now included in the priority review process by the National Medical Products Administration [1] Group 1 - The drug Luwo Meitin (generic name: Luwo Meitin tablets) is a selective inhibitor of MEK1/2 [1] - The drug has already been approved for two indications in mainland China (excluding Hong Kong, Macau, and Taiwan) [1] - The approved indications include treatment for adult patients with Langerhans cell histiocytosis and tissue tumors, as well as for children and adolescents aged 2 years and older with symptomatic, inoperable plexiform neurofibromas [1]